A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
Proteinuric Kidney Disease
Спонсор: Maze Therapeutics
Налично на:
БГ
Обобщение
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Описание
An open-label Phase 2 study is designed to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype.
Кой може да участва
Key Inclusion Criteria:
* APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2
* Chronic kidney disease with persistent albuminuria
Key Exclusion Criteria:
* Organ or bone marrow transplantation
* History of cancer within past 2 years, excepted for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer
* Conditions that may alter drug absorption, e.g., history of bariatric surgery
* Type I diabetes
* Pregnant or currently nursing
Other inclusion/exclusion criteria defined in protocol apply.
БГ
EN